Faron Pharmaceuticals Oy (LON:FARN) Trading Down 6.2%

Faron Pharmaceuticals Oy (LON:FARN)’s share price dropped 6.2% on Friday . The stock traded as low as GBX 82 ($1.07) and last traded at GBX 83.50 ($1.09), approximately 132,602 shares were traded during trading. An increase of 814% from the average daily volume of 14,501 shares. The stock had previously closed at GBX 89 ($1.16).

The company has a debt-to-equity ratio of 577.78, a current ratio of 0.88 and a quick ratio of 0.64. The stock has a market capitalization of $32.86 million and a P/E ratio of -0.76. The company’s 50 day simple moving average is GBX 105.44 and its two-hundred day simple moving average is GBX 96.96.

About Faron Pharmaceuticals Oy (LON:FARN)

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company's lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS).

Recommended Story: What is a capital gain?

Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.